lars freurgaard ceo of novo nordisk. >>> let's pivot to commodities, materials. i don't have a pivot apart from the fact that they're both exposed to the global market in china. >> share buybacks, maybe bhp announced a buyback program, it will be split between a buyback and a special dividend the stock price moving higher. and gdandanske cited a 1.5 billn krona donation to initiatives against financial crime. denmark's largest lender is involved in a money marketing scandal at its estonia outlook a lot of other metrics in the business look strong despite the extent of this scandal >>> coming up, we llpe twi sako john dacey, that's next. >>>credit swiss in the read after missing forecasts, despite jumping over 70% tidjane thiam saying the environment remains challenging. >> there is a disconnect between the condition of the economy, if you wish, and the psychology and mindset in markets we see big volumes when the market goes down, small markets when the market goes up. >>> bt edges its full-year outlook higher after the profit jumps 2% the outgoing ceo says while

now, we see that right now, novo nordisk is winning based on our latest innovations. has announced they lilly hasthat -- eli announced they have data that could lead to a strong product. things we can launch in a couple of years. in our pipeline, we have next-generation opportunities where we believe we can match or even beat what lilly is bringing forward. this is a classic pharmaceutical positive which is because there are two companies aiming at expanding the markets and driving up the value of the markets, for the benefit of patients getting better products. therapy thatne novo nordisk once to get involved with, if not, how will your hemophilia portfolio perform? in gene are not yet therapy. what we're focusing on is stem cell-based therapy, not particularly in hemophilia, but working with cells is something we know very well. we are investing significantly in stem cell based therapy. forave opportunities competing on the longer-term, the right now it is not based on gene therapy. matt: let me ask about the possibility of m&a. do you think you need to pursue acqui

also on the upside, novo nordisk is up 3.6%.rn we could see pressure on the homebuilders with house price data out of the u.k. but also the ongoing political crisis over brexit. berkeley trading down 1.5%, but nothing too dramatic. performer, he worst arkema down 2.9%. anna? anna: that's the market open. that's how we position this morning. i'm at the confederation of british industry's annual conference, what theresa may will try to sell her brexit deal to businessman. a possible leadership challenge. joining us on set is stephen isaacs, chairman of the investment committee. you say in your notes of the eu is misunderstanding the entire brexit situation. what do you mean and where does that take us next? stephen: good morning. what i'm saying is we're commemorating the 100th anniversary of the first world war. and what came after that was the treaty of versailles. and the treaty of versailles was misconstrued right from day one in the sense that the victorious powers extracted a very tall against germany. and we know what happe

novo nordisk. we were looking at diabetes pressures on them. a few numbers going through. nine-month sales coming in at 82.1 billion danish krone. a novo has experiment -- approved the expansion of the share program to one billion danish krone. operating profit, that fell by 6%. just a few headlines coming through. we will wait for more of them, but some of the numbers on novo. ? let's give you a quick summary and credit suisse. manus: basically, they have missed. there is a full t live discussion with all the editors. third suisse, net income, quarter the concern was what would happen within the private wealth. the outlook for the global economic growth in the fourth-quarter remains positive. funding and restructuring 10%.es will lift to they say they are on track for less than 17 billion francs of cost. this bank has delivered losses for three years in a row. tidjane thiam was supposed to turn the corners on this. net new money, 14.8 billion. further profit improvements into 2019. the man with the answers is of course the ceo, tidjane thiam. he will join francine lacqua v